BioNTech's Two-Sided Story: Oncology Wins Collide With a Shrinking Vaccine Franchise

BioNTech trades near EUR 87 as UBS reaffirms buy after strong gotistobart data, while BMO's downgrade flags Comirnaty erosion and pipeline risks.

Rarely do euphoria and sobering reality sit so close together in a single stock as they do at BioNTech right now. Promising oncology data pulls one way; an analyst warning about the very risks accompanying the company's restructuring pulls the other. Understanding why the share price refuses to break out despite good news means weighing both sides at once.

The stock traded at EUR 86.95 on Friday, roughly 1.1% above the prior day's close and about 3% above its 50-day average of EUR 84.44. The recovery from the 52-week low of EUR 68.35 has been notable, yet the shares still sit 18% below January's high of EUR 105.80. That gap is where the real story lives: BioNTech is a company in transition, and the market has yet to decide which narrative deserves more weight.

The pivot away from vaccines

BioNTech built its reputation on Comirnaty, the COVID-19 vaccine that funneled billions into the Mainz-based company's coffers. That business is now contracting faster than expected. On September 8, BMO Capital Markets downgraded the stock from "Outperform" to "Market Perform" and slashed its price target from USD 128 to USD 105.

The brokerage cited a sharper-than-anticipated erosion of the Comirnaty franchise, a lack of near-term data to assess the risk profile of the active ingredient Pumitamig, and muted expectations for the mRNA-based individualized neoantigen vaccine program. That is no throwaway footnote — it is a warning to anyone casually labeling BioNTech "tomorrow's cancer stock." The business model overhaul is not proceeding in a straight line, and declining revenue from the old franchise hits while the new one is still being built.

The picture darkened further when a study of autogene cevumeran, the company's personalized mRNA cancer vaccine, was discontinued. An independent monitoring committee concluded roughly two weeks ago that continuing the trial offered no prospect of further efficacy. Setbacks like this are part of oncology research, but they serve as a reminder that not every pipeline project will replicate the success of the recent lung cancer data.

Gotistobart as a counterweight

Those lung cancer results form the second half of the story. On Monday, BioNTech and partner OncoC4 presented updated Phase 3 data on gotistobart at the World Conference on Lung Cancer. In previously treated patients with metastatic squamous non-small cell lung cancer, median overall survival nearly doubled compared with standard chemotherapy. Reuters called the benefit clinically meaningful.

Separately, in Seoul, BioNTech showed initial data on combining Pumitamig with Elfetabart Drozuntecan — a signal that the oncology pipeline is broader than any single program.

Two analyst verdicts, one unsettled market

The most recent analyst reaction came from UBS, which reaffirmed its buy rating on September 16 following the gotistobart data, accompanied by a premarket gain. That is the freshest assessment on the table, and it carries more weight than older calls. The BMO downgrade, by contrast, dates from September 8 — before the gotistobart announcement — and thus reflects a different information set than the one the market is working with today. Reading it as a current counterpoint to the UBS confirmation would be a mistake; it is better understood as a snapshot from a period when BioNTech was grappling with mixed news.

The pipeline itself is not a pure success story. Roughly two weeks ago, BioNTech halted a study of its mRNA cancer vaccine candidate in the colorectal carcinoma indication after an independent committee concluded that an improvement in overall survival was unlikely. US-listed shares fell 7.5% at the time. The stock has since recovered — evidence that the market distinguishes between individual pipeline setbacks and the company's broader substance.

Charting the space between fear and euphoria

On the technical side, the shares closed Thursday at EUR 85.75, up 2.6%, sitting just above both their 50-day average of EUR 84.29 and their 200-day average of EUR 84.20 — a neutral-to-slightly-positive picture. More telling is the distance from the 52-week low of EUR 68.35, struck on March 10: the stock now trades well over a quarter above that level. Against the 52-week high of EUR 105.80 reached in late January, nearly a fifth of upside is still missing. The market has rewarded the gotistobart data but has not converted that into euphoria.

An annualized volatility of 72% is a reminder that sharp moves remain possible in either direction — extraordinarily high even by biotech standards. The RSI of 51.6 points to a market neither overheated nor oversold, a stock balanced between two narratives. Year-to-date performance of 6.9% confirms that the good news has slightly outweighed the bad.

What remains is the central test for the quarters ahead: whether the oncology pipeline can grow fast enough to offset the shrinking Comirnaty business before the cash cow runs dry. Anyone buying BioNTech today is no longer purchasing the COVID story of 2021 — they are wagering that the cancer franchise can take its place in time.